Vedolizumab, MLN0002, Ulcerative colitis, Crhon's disease, integrin inhibitor, Remicade, Humira, Simponi, Tysabri, Etrolizumab, Tofacitinib, GEMINI 1 2, STELARA, GSK-1605786, Vercirnon, Traficet-EN - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28651/-Vedolizumab,-MLN0002,-Ulcerative-colitis,-Crhons-disease,-integrin-inhibitor,-Remicade,-Humira,-Simponi,-Tysabri,-Etrolizumab,-Tofacitinib,-GEMINI-1,2,-STELARA,-GSK-1605786,-Vercirnon,-Traficet-EN--/

Takeda received priority review status from US FDA for its late stage candidate Vedolizumab (filed for UC and Crhon’s disease (CD), a4ß7 integrin inhibitor) to treat ulcerative colitis indication. Vedolizumab targets the disease by preventing leukocyte extravasations through inhibiting a4ß7 integrin in the gut which is different from currently used second line options, mainly anti-TNFs (Remicade, Humira, Simponi). The key limitations with these drugs are their low response rate (~40% do not respond) and lost of response over time (~30%-40%). We understand that dose escalation and switch to a second anti-TNF recapture the response in 40-80% of patients but after 12 months the response rate drops significantly. This creates a huge unmet need for a drug which ..............On pipeline front..............The report discuss in details unmet need, late stage pipeline drugs and competitive landscape of ulcerative colitis and crohn's disease treatment options.

CADILA HEALTHCARE , Lipaglyn Launched in India – Survey suggests quick market acceptance, if priced appropriately - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28650/CADILA-HEALTHCARE-,--Lipaglyn-Launched-in-India-%E2%80%93-Survey-suggests-quick-market-acceptance,-if-priced-appropriately/

Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn with statin as important for the quick ramp up for this novel compound.

Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28652/Treating-Refractory-Hematological-Malignancies-%E2%80%93-Multiple-Myeloma-(MM):-New-Treatment-Options-Driving-In-Licensing-and-M&A/

The report (ToC) provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them. 

Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

MORPHOSYS (MOR) - MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28653/MORPHOSYS-(MOR)---MOR103/-MOR202-%E2%80%93-Partnering-is-the-Beginning-of-a-New-Phase-of-Growth-/

Alliances with GSK and Celgene in 2013 propelled MorphoSys (MOR) in the limelight. This could well be the inflection point in MorphoSys's evolution into a successful mature biotech company on the strength of its innovative platforms to develop biologics. Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are the future drivers. MOR enter into out-licensing deal with CELG for jointly development of MOR-202 (HuCAL antibody targeting CD38) for a total value of €698.8m. CELG strong presence in hematological malignancy further enhances the value with possible expansion in other leukemia’s....... For more detail, please read our report released on September 12, 2013, titled, “MOR103/ MOR202 – Partnering is the Beginning of a New Phase of Growth ”.

Amgen (AMGN) - Onyx Acquisition - Maturing Pipeline - Biosimilar Opportunity - Better Poised Than Large Pharma - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28662/Amgen-(AMGN)---Onyx-Acquisition---Maturing-Pipeline---Biosimilar-Opportunity---Better-Poised-Than-Large-Pharma/

Amgen (AMGN) announced the acquisition of Onyx pharma at $125/sh or $10.4b ($9.7b net of est. Onyx cash) in net cash, strengthening its Oncology/ Hematology drug portfolio ($7b in 2012, 42% of total sales) by adding Onyx’s marketed products – Kyprolis (L in US, RRMM, proteasome inhibitor, ex-JP rights), Nexavar (sorafenib, RCC, HCC, profit-sharing ex.JP) and Stivarga (regorafenib, mCRC, GIST, 20% royalties on WW sales). For Nexavar and Stivarga, Amgen has co-promotion agreement with Bayer in the US. This merger is synergistic and will be accretive to adj. EPS aided by cost savings from 2015. Amgen changed its approach to increase... For more detail, please read our report on AMGN released on 12th Sept. 2013, titled, "Onyx Acquisition + Maturing Pipeline + Biosimilar Opportunity = Better Poised Than Large Pharma!"

Generic Advair – 3 years to go, but which generic companies are better poised - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28663/Generic-Advair-%E2%80%93-3-years-to-go,-but-which-generic-companies-are-better-poised/

The USFDA has finally announced the draft guidance for the development of generic version of GSK’s Asthma / COPD drug – Advair (Fluticasone propionate + Salmeterol Xinafoate). The guidelines pave the way for generic companies to launch a substitutable and interchangeable version of Advair in the US market, which should allow easy and larger penetration for generic copies. Apart from ANDA filings, we should also see a few companies which are developing an improved formulation or using a different device file through the 505(b) (2) route. We see Mylan and Sandoz are well positioned to enter the market in 2016 with a fully substitutable version, while we are not sure if Cipla could also do the same. Sun Pharma also has access to dry powder inhaler technology (starhaler), but the efficacy profile of its formulation is quite different from Advair, hence it may have to come through the 505(b) (2) route. Teva has recently acquired Microdose therapeutx, which gives it access to DPI technology, hence there is a chance that Teva could also accelerate development of a fully substitutable version of Advair.

GSK – FDA Advisory committee positive on Anoro Ellipta – First once daily dual bronchodilator for US COPD patients - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28656/GSK-%E2%80%93-FDA-Advisory-committee-positive-on-Anoro-Ellipta-%E2%80%93-First-once-daily-dual-bronchodilator-for-US-COPD-patients/

GSK and Theravance jointly announced that the FDA pulmonary allergy Drugs Advisory Committee recommended in favor of approval (11-2) for the once daily, lower dose regimen (Vilanterol-62.5 mcg/ Umeclidinium 25 mcg). The committee unanimously voted in favor of efficacy, while safety votes were divided (10-3). The higher dose (125/25 mcg) of Anoro was not considered by USFDA for voting. The PDUFA date of Anoro is Dec 18, 2013 and a timely approval will make Anoro the first dual bronchodilator to be launched in the US. We expect Anoro to garner global peak sales of $ 1.5b. Anoro once launched will cannibalize the market of twice daily LABA’s (formoterol and Salmeterol) and Spiriva. LABA’s are primarily co-prescribed as second line treatment agents in COPD patients and about 25-30% of Spiriva prescriptions have LABA’s as coprescribed drugs. We see the market for Spiriva getting impacted to that extent. The MAA (Europe) for Anoro has already been filed in Europe and expected to receive approval by the end of this year. The submission of the regulatory application to the Japanese ministry has been done in Apr 2013.GSK and Theravance jointly announced that the FDA pulmonary allergy Drugs Advisory Committee recommended in favor of approval (11-2) for the once daily, lower dose regimen (Vilanterol-62.5 mcg/ Umeclidinium 25 mcg). The committee unanimously voted in favor of efficacy, while safety votes were divided (10-3). The higher dose (125/25 mcg) of Anoro was not considered by USFDA for voting. The PDUFA date of Anoro is Dec 18, 2013 and a timely approval will make Anoro the first dual bronchodilator to be launched in the US. We expect Anoro to garner global peak sales of $ 1.5b. Anoro once launched will cannibalize the market of twice daily LABA’s (formoterol and Salmeterol) and Spiriva. LABA’s are primarily co-prescribed as second line treatment agents in COPD patients and about 25-30% of Spiriva prescriptions have LABA’s as coprescribed drugs. We see the market for Spiriva getting impacted to that extent. The MAA (Europe) for Anoro has already been filed in Europe and expected to receive approval by the end of this year. The submission of the regulatory application to the Japanese ministry has been done in Apr 2013.

Edoxaban – HOTSUKAI VTE STUDY Results at ESC-13- Well differentiated and should carve its niche in VTE patients with PE/Renal impairment - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28657/Edoxaban-%E2%80%93-HOTSUKAI-VTE-STUDY-Results-at-ESC-13--Well-differentiated-and-should-carve-its-niche-in-VTE-patients-with-PE/Renal-impairment-/

On 1st Sep, at ESC, Daiichi-Sankyo presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy and superiority in terms of safety compared to warfarin in the trial. The results are on the same lines as Eliquis and better than Xarelto and Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with a Pulmonary embolism (with or without DVT) and also those with renal impairment. We expect the market size for VTE treatment to be.....................
HOKUSAI –VTE Implications for ENGAGE-AF.........................

SymBio pharma - TREAKISYM Label Expansion - Rigosertib’s Potential in MDS market - Cash to In-license More - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28664/SymBio-pharma---TREAKISYM-Label-Expansion---Rigosertib%E2%80%99s-Potential-in-MDS-market---Cash-to-In-license-More/

SymBio (4582) licensed Onconova’s Rigosertib (SyB L-1101, PhI, RRMDS, Dual inhibitor of PI-3 and PL-1 Kinase Inhibitor) and gained Japan/Korea rights in 2011. Onconova Therapeutics (ONTX) debut in NASDAQ has been very encouraging and should percolate into SymBio especially in light of the upcoming PhIII data in US of Rigosertib IV (Rig. IV) in RRMDS by YE13. Disappointing guidance of TREAKISYM (bendamustine hydrochloride, L, rrNHL, MCL) sales for FY13 (¥1,563m, lowered down by ~¥365m) hit the stock, but future potential of its product portfolio remains intact with... For more detail please read our report on SymBio released on 3rd Sept. 2013, titled, "TREAKISYM’s Label Expansion + Rigosertib’s Potential in MDS market + Cash to In-license More!"

Celgene (CELG) - Label Expansion of Marketed Product and Newly Drug launches - Maturing Pipeline - Long Term Gain - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28665/-Celgene-(CELG)---Label-Expansion-of-Marketed-Product-and-Newly-Drug-launches---Maturing-Pipeline---Long-Term-Gain/

CELG’s Maturing pipeline through its own proprietary compounds and acquisition/in-licensing should keep the momentum positively in coming years. New launches – POMALYST (L, Pomalidomide, RRMM), Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013) should sustain the growth for long term. CELG has recently raised $1.5b in senior notes strengthening its balance sheet and continues it buyback plans ($3b announced in June 2013). We expect ... For more detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain".

Onconova Therapeutics (ONTX) -Near-Term Catalysts = Upside Still! - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28660/Onconova-Therapeutics-(ONTX)--Near-Term-Catalysts-=-Upside-Still!/

Onconova Therapeutics (ONTX) debut on NASDAQ (IPO: 5.9m share offering @ $15 July 25, 2013) has been impressive (30% up since IPO), raising the inevitable question – Is this the upper limit or is there still room for upside? Estybon is targeting a niche patient pool, where unmet medical needs remain due to lack of effective treatment or no approved therapies. Rig. IV showed median overall survival of 35 weeks in four early-stage PhI/II trials in pts with 2nd-line Higher Risk MDS vs. less than six months offered by current standard of care (as per historic peer-reviewed published reports). Our risk reward analysis indicates that ONTX's lead drug, Estybon (Rigosertib/ ON 01910.Na, PhIII, PI3K-PLK inhibitor, partnered with Baxter for EU rights and SymBio pharma for Japan & Korean rights) is ... For more detail please read our report on Onconova released on 30th August 2013, titled, "Near-Term Catalysts = Upside Still!"

Ambit Biosciences (AMBI) - Early Approval of Quizartinib in RR-AML = A Risk Worth Taking - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/28661/Ambit-Biosciences-(AMBI)---Early-Approval-of-Quizartinib-in-RR-AML-=-A-Risk-Worth-Taking/

Regaining WW rights to Quizartinib (PhII/III, a selective oral potent FLT3, FMS like tyrosine kinase-3 inhibitor for acute myeloid leukemia, AML) from Astellas in 2013 armed AMBI to tap the unmet need in refractory/ relapsed AML (RR AML) and related hematological disorders. In the PhIIb study pts, FLT3 positive AML patients relapsed/refractory to one or more prior therapies treated with quizartinib achieved CRc rates of 46% vs.3-4% seen with other tyrosine kinase inhibitors. FDA is reviewing the data, new endpoints and is likely to announce its decision by Nov 2013. The drug has a fast track in orphan status and the company is on track to start the PhIII trial in 2014 in rrAML irrespective of the FDA’s decision. Even if the drug does not get approved in ... For more detail please read our report on Ambit released on 30th August 2013, titled, "Early Approval of Quizartinib in RR-AML = A Risk Worth Taking".

Big Data and Telecom Analytics Market: Business Case, Market Analysis & Forecasts 2014 - 2019 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27726/Big-Data-and-Telecom-Analytics-Market:-Business-Case,-Market-Analysis-&-Forecasts-2014---2019/

Big Data refers to a massive volume of both structured and unstructured data that is so large that it is difficult to process using traditional database and software techniques.  While the presence of such datasets is not something new, the past few years have witnessed immense commercial investments in solutions that address the processing and analysis of Big Data.
 
Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
 
With access to vast amounts of data sets, telecommunications companies are emerging as major proponents of the Big Data movement. Big Data technologies, and in particular their analytics abilities, offer a multitude of benefits to telecom companies including improved subscriber experience, building and maintaining smarter networks, reducing churn, and generation of new revenue streams. 
 
Mind commerce, thus expects the Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
 
This report provides an in-depth assessment of the global Big Data and telecom analytics markets, including a study of the business case, application use cases, vendor landscape, value chain analysis, case studies and a quantitative assessment of the industry from 2013 to 2019.
 
Topics covered in the report include: 
• The Business Case for Big Data:  An assessment of the business case, growth drivers and barriers for Big Data 
• Big Data Technology:  A review of the underlying technologies that resolve big data complexities
• Big Data Use Cases:  A review of investments sectors and specific use cases for the Big Data market  
• The Big Data Value Chain:  An analysis of the value chain of Big Data and the major players involved within it
• Big Data in Telco Analytics:  How telecom can utilize Big Data technology to reduce churn, optimize their networks, reduce risks and create new revenue streams
• Telco Case Studies:  Case Studies of two major wireless telecom capitalizing on Big Data to reduce churn and improve revenue
• Vendor Assessment & Key Player Profiles:  An assessment of the vendor landscape for leading players within the Big Data market
• Market Analysis and Forecasts:  A global and regional assessment of the market size and forecasts for the Big Data market from 2014 to 2019
Key Findings:
• Big Data opens a vast array of applications and opportunities in multiple vertical sectors including, but not limited to, retail and hospitality, media, utilities, financial services, healthcare and pharmaceutical, telecommunications, government, homeland security, and the emerging industrial Internet vertical.
• Mind Commerce has determined that IBM leads the Big Data market in terms of current investments (from a vendor perspective), with estimated revenue for $1.3 Billion in 2012 for its Big Data services, software and hardware sale
• Despite challenges such as the lack of clear big data strategies, security concerns and the need for workforce re-skilling, the growth potential of Big Data is unprecedented. Mind Commerce estimates that global spending on Big Data will grow at a CAGR of 48% between 2014 and 2019. Big Data revenues will reach $135 Billion by the end of 2019
• Big Data technologies, and in particular their analytics abilities offer a multitude of benefits to telecom including improving subscriber experience, building & maintaining smarter networks, reducing churn and even the generation of new revenue streams
• The Big Data driven telecom analytics market to grow at a CAGR of nearly 50% between 2014 and 2019. By the end of 2019, the market will eventually account for $5.4 Billion in annual revenue.
Target Audience:
• Investment Firms
• Media Companies
• Utilities Companies
• Financial Institutions
• Application Developers
• Government Organizations
• Retail & Hospitality Companies
• Other Vertical Industry Players
• Analytics and Data Reporting Companies
• Healthcare Service Providers & Institutions
• Fixed and Mobile Telecom service providers
• Big Data Technology/Solution (Infrastructure, Software, Service) Vendors

Australia Solar Power Sector Opportunity Analysis - Reports Corner

For complete information about the report, please visit our website


https://www.reportscorner.com/reports/27512/Australia-Solar-Power-Sector-Opportunity-Analysis/



As Australia is moving towards increased solar power generation, the installed capacity of solar modules has shown considerable growth in the recent years. The use of solar energy for power generation had started way back in 1992 in the country with a few pilot projects and an installed capacity of 7.3 MW. With Australia’s power generation dominated by fossil fuels and a lack of clear solar energy policies and growth framework, the installed capacity could not grow more than 2 to 5 MW per year till 2001. Also, this period saw a growth in hydro and wind power production systems indicating the government’s focus on the other known and technologically available sources of clean energy. Post 2001, the installed capacity addition was in the range of 5 to 12 MW till 2007 on a per year basis. It was only in 2007 when solar power production gained weight and the installed capacity started growing by a larger margin. 
The last couple of years (2011 & 2012) have truly been the solar years for Australia with solar announcing its arrival in a grand manner. More than 1.6 GW was added in last two years which have given solar power development the required momentum. This was achieved through a change in policies and a greater shift of focus of the government from other renewable sources to solar energy. Solar PV in Australia is divided into four sub markets namely, Off-grid domestic, off-grid non-domestic, grid-connected distributed and grid-connected centralized. These four sub markets signify the distribution of the installed capacity in the country. 
Solar PV technology is bound to play a larger role in the electricity production sector of Australia which will certainly be augmented by the increasing investments and positively shaping policies. The government is keen on exploiting all its energy sources and solar being one of the most abundant has taken priority over others. The technology is entering its advanced stage and Australia looks set to embrace the solar energy giving it a bigger share in power generation in the coming years.

“Australia Solar Power Sector Opportunity Analysis” discusses following key issues related to solar power development in Australia:
• Australia Power Sector Overview
• Solar Radiation & Potential
• Grid Connected & Off Grid Solar Capacity
• Domestic & Commercial Solar Capacity
• Feed in Tariff Structure by State
• Photovoltaic Module Manufacturing
• Development of Solar Cities
• Regulatory & Policy Initiatives
• Competitive Landscape

Telecom Managed Services: The Market for Machine-to-Machine (M2M) Managed Service Providers - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27725/Telecom-Managed-Services:-The-Market-for-Machine-to-Machine-(M2M)-Managed-Service-Providers/

Overview:

Machine-to-machine (M2M) communications is a technology that is transforming the way that business is conducted, impacting everything from traditional telephony and IT operations to ERP, SCM, public safety, homeland security, and more.  Traditionally the realm of utilities and SCADA systems, M2M is expanding into many new industries, market segments, applications, and use cases.  Several new areas hold great promise including connected vehicles and healthcare.

The M2M ecosystem is complex and includes device manufacturers, wireless service providers, integrators, platform providers and developers.   There are many drivers for managed services within the M2M value chain.  The report evaluates the M2M market, drivers for managed services providers, competitive marketplace, and provides conclusions and recommendations for players within the value chain.

This research is a must-read for anyone within the M2M community including mobile network operators and other service providers, infrastructure providers, managed service providers, and more.

Target Audience:
• Mobile network operators
• Managed services providers
• Systems integration companies
• Application developers and ASP
• Network integration companies
• Network infrastructure providers
• Enterprise companies of all types
• Investment and M&A companies of all types
• M2M equipment and service providers of all types

Machine-to-Machine (M2M) Business Case: Solutions, Business Models, and ROI by Industry Vertical - Reports Corner

For complete information about the report, please visit our website]

https://www.reportscorner.com/reports/27724/Machine-to-Machine-(M2M)-Business-Case:-Solutions,-Business-Models,-and-ROI-by-Industry-Vertical/

Overview:
 
The Machine-to-Machine (M2M) market is seen as the future for wireless revenue growth with various reports touting market size to reach 50 billion connections by 2020. However, the current market is still under 100 million connections.
 
Since M2M is not the only service for telecom carriers, rather it is not their core service; strategies adopted for M2M cannot be studied on stand-alone basis. The strategies have to be evaluated in context with other strategic initiatives taken by the companies. Hence, over-all strategies have also been discussed in this write-up.
 
This research provides analysis of the business case for M2M from the industry vertical or market segment perspective including specific cases within Healthcare, Vending, Petroleum (Oil & Gas and Propane), and Fleet Management.  The report includes business model analysis, technical solution evaluation, and ROI assessment.
 
The expansion of M2M beyond its roots in utilities and manufacturing industries into many different enterprise operations has opened a host of new opportunities across the entire ecosystem.  Furthermore, various enterprise companies in new industries are making plans to leverage M2M in processes that represent a major shift beyond previous implementations.
 
The information in this report is very valuable to industries/segments address as they assess the M2M business case as well as the M2M service providers as they seek to optimize their respective M2M offerings.
 
Target Audience:
• Mobile network operators
• Systems integration companies
• Enterprise companies of all types
• Investment and M&A companies of all types
• M2M equipment and service providers of all types

Next Generation 9-1-1: Providers and Solutions 2013 - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27615/Next-Generation-9-1-1:-Providers-and-Solutions-2013/

Next Generation 9-1-1 ( NG9-1-1) is an initiative that targets updating the 9-1-1 emergency service infrastructure in USA and Canada in order to improve public emergency communications services. The Improvement includes adding text messages, images, video and data beside the traditional phone calls for 9-1-1 service. 
 
This report provides information about NG9-1-1 providers. The report presents analysis for each provider including overview, products and services as well as SWOT analysis which introduces strength points, weaknesses, opportunities and threats.
 
Target Audience:
• Managed service providers, service bureau companies
• Public safety organizations and governmental agencies
• VoIP and Internet Infrastructure as a Service (IaaS) companies
• Wireless service providers: cellular network operators, WiMAX and WiFi
• Wireless vendors including hardware, software and service providers

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27617/Obesity-Therapeutics-to-2019---Safety-Concerns-Hinder-Drug-Performance-Despite-Large-Market-Opportunity/

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market.

Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity.

Scope

- The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs.
- A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options
- Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period
- Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
- Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
- An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.
- A detailed discussion of the drivers and barriers for this immature market.

Reasons to buy

The report will enhance your decision-making capability by allowing you to - 
- Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
- Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
- Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
- Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals.

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27616/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification,-Increasing-Efficacy,-and-Pipeline-Innovation-Combine-to-Drive-Growth/

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope

- A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.
- In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
- Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
- Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.
- Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.
- Discussion of the drivers and barriers for market growth or decay.

Reasons to buy

- Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.
- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
- Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.
- Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. 
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27040/Purified-Terephthalic-Acid-Global-Market-to-2020---Overcapacity-and-Declining-Margins-to-Hinder-Global-Demand-in-the-Short-Term/

Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term

Summary

GBI Research’s "Purified Terephthalic Acid Global Market to 2020 - Overcapacity and Declining Margins to Hinder Global Demand in the Short Term" is an in-depth report focusing on the demand side of the global Purified Terephthalic Acid (PTA) industry. The report provides the reader with detailed analysis and forecasts of the major economic and market trends expected to affect global PTA demand in all major regions of the world. It also provides analysis and description of the major drivers and restraints affecting PTA demand in various regions. Global PTA demand is assessed in terms of end-user segments, price, and competitive landscape, at both the regional and national level.

Scope

- Drivers, restraints and challenges affecting the growth of the PTA market for all the major regions: Asia-Pacific, Europe, North America, the Middle East and Africa, and South and Central America
- Demand and production volume forecasts for the PTA markets of all major countries in the respective regions worldwide
- Demand volume forecasts for the major end-user applications, highlighting trends and volume share analysis for each of these applications in all major countries
- Pricing forecasts and analysis for the major countries and regions
- PTA import and export trends in all the major countries
- Competitive landscape for the PTA market, for major regions and major countries

Reasons to buy

- An understanding of regional PTA market dynamics, through detailed demand and production forecasts, end-use data and competitive landscape analysis
- Detailed analysis at a country level, enabling the buyer to evaluate opportunities in emerging markets and quantify potential returns on investment
- A detailed understanding of the factors that are expected to affect the growth of the PTA market in different regions of the world
- An identification of the most attractive geographical locations, product segments and end-user applications, in order to increase business revenue
- Understanding of market dynamics and pricing differences between countries, which provides an insight into arbitrage opportunities in terms of trade across countries
- The ability to develop custom strategies, based on current and forecast trends in the production and consumption of PTA
- Advanced insight into each of the major markets, through detailed forecasts for demand, production and end-user analysis
- The ability to benchmark different geographies according to previous and forecast growth of demand, production and end-use of PTA
- Gain knowledge regarding the market shares held by each of the major producers in the PTA market in different regions of the world

India Renewable Energy Sector Opportunity Analysis - Reports Corner

For complete information about the report, please visit our website

https://www.reportscorner.com/reports/27574/India-Renewable-Energy-Sector-Opportunity-Analysis-/

Renewable energy is deemed as the future of energy and India is working in that direction with its various policies. The government has planned a number of projects that would be launched in the next few years and these will enhance India’s renewable energy status. The research and development phase has already passed and the execution of projects is underway. Given the different policies and incentive packages launched by the government to attract investment in the sector, renewable energy in India is bound to grow at an unprecedented pace. The basic infrastructure has been set up that will facilitate the future of renewable energy in the country.
Indian Government gives multiple benefits to renewable energy projects such as no need for industrial clearance, availability of loan, excise duty exemption, custom duty concession, financial support to renewable energy’s R&D projects, income tax holiday, accelerated depreciation, preferential tariffs, interest and capital subsidies, energy buy-back and third party sale and trading. At the same time, the Government is also trying to reduce the capital cost of renewable energy projects so that more and more companies can invest in the sector. To fulfil this aim, Government is trying to adopt latest and suitable technologies in the sector and promote healthy competition among the players.
India is one of the few countries to have set up an independent ministry to overlook the growth of renewable energy. The Ministry of New and Renewable Energy is the authority that launches the various schemes and projects to enunciate the renewable energy growth and to see that the schemes are properly utilized for the benefit of the nation. MNRE has proposed many schemes that will determine the future of renewable energy in India. These projects will establish a proper growth strategy in the future for the exploitation of the huge potential of renewable sources of energy in the country. There is a large amount of renewable energy potential that can be developed with help from the incentive schemes initiated by the ministry.
In FY’2013, around 57% of the total electricity produced used coal as the source of fuel to generate electricity, 17% power was produced by hydro or water based sources, 12% electricity was generated using renewable energy sources and gas contributed 9% to the total power generation. Government has set a target to generate 53,000 MW from renewable energy sources by 2017. To achieve this ambitious target government has introduced several programs such as Generation Based Incentives (GBI), Renewable Energy Certificates, Feed-in-Tariff (FIT) support, solar specific, Renewable Purchase Obligation (RPO), Generation Based Incentives (GBI) and long term PPAs. 

“India Renewable Energy Sector Opportunity Analysis” Report gives detailed overview on the following aspect related to renewable energy sector in India:
• Significance of Renewable Energy for India 
• Renewable Energy Potential & Installed Capacity by Source
• Government Support & Incentive Framework
• Current Scenario of Decentralize/Off Grid Renewable Energy
• Emerging Sources of Renewable Energy: Hydro, Geothermal & Tidal energy.
• Policy & Regulatory Framework
• Jawaharlal Nehru National Solar Mission
• Future Outlook for Renewable Energy